Peptide Therapy in Alpharetta

What a peptide actually is

Peptides are short chains of amino acids — shorter than a full protein, but built from the same building blocks. Many hormones and cell-signaling molecules in the human body are peptides; insulin and growth hormone-releasing hormone are two familiar examples. That biological role is exactly why interest in synthetic and semi-synthetic peptides has grown so quickly in performance and longevity medicine: if a molecule already has a signaling job in the body, researchers want to know whether a synthetic version can be used deliberately, safely, and to good effect. The honest answer, compound by compound, is "sometimes, partly, and not yet proven" more often than marketing in this category admits.

At Aeon, peptide therapy sits inside our clinical tier alongside clinic and lab services and hormone therapy. We are a performance and longevity studio, not a pharmacy or a compounding facility, and we do not sell peptides directly. Where a licensed provider determines a protocol is appropriate for a specific member, it is prescribed, sourced, and monitored through that provider's own clinical channels — never dispensed off a menu.

The categories our providers work with

The 13 compounds covered on this site fall into a small number of purpose groups. We organize them this way because the honest evidence position is different in each group, and because most members are interested in a category — recovery, sleep, metabolic health — rather than a specific molecule name they found online.

Recovery and tissue repair. Compounds studied for their role in soft-tissue healing, most of it in animal and cell-culture models rather than completed human trials.

• BPC-157 peptide therapy — a gastric-derived peptide studied in animal models of tendon, ligament, and gut-lining healing, and currently on the World Anti-Doping Agency's prohibited list.
• TB-500 peptide therapy — a synthetic fragment of thymosin beta-4 studied preclinically for cell migration and soft-tissue repair.
• KPV peptide therapy — an alpha-MSH-derived tripeptide studied mostly in colitis and other inflammatory animal models.

Growth hormone axis. Compounds that act on growth-hormone-releasing pathways, with evidence ranging from early-phase human pharmacokinetic data to discontinued development programs.

• CJC-1295 peptide therapy — a growth-hormone-releasing hormone analogue with early-phase human data on GH and IGF-1 elevation.
• Ipamorelin peptide therapy — a selective ghrelin-receptor agonist with limited human data and a discontinued development history.
• Tesamorelin peptide therapy — the one compound in this list with genuine FDA approval, and only for a specific, narrow indication we explain in full on its page.

Metabolic. Compounds studied for effects on body weight, glucose handling, or fat metabolism.

• GLP-3 — the popular nickname for retatrutide, an investigational triple agonist in active phase 3 trials, not FDA approved, and not something Aeon supplies.

Cellular and longevity. Compounds studied for roles in cellular energy production and mitochondrial function, with evidence still concentrated in preclinical or early human work.

• NAD+ peptide therapy — technically a coenzyme rather than a peptide, discussed here because it is so often grouped with them, with human trials of its precursors showing reliably raised NAD+ levels but inconsistent functional benefit.
• MOTS-c peptide therapy — a mitochondrial-derived peptide studied almost entirely in rodent models of exercise metabolism.

Immune. Compounds studied for immune modulation, with one carrying approval outside the United States.

• Thymosin Alpha-1 peptide therapy — approved in some countries for hepatitis B and as an immune adjuvant, but not FDA approved in the United States.

Sleep. A compound studied decades ago with mixed and dated human data.

• DSIP peptide therapy — delta sleep-inducing peptide, studied in small, older human trials with inconsistent results.

Skin. A compound with its strongest evidence in a different application than most people assume.

• GHK-Cu copper peptide therapy — a copper-binding peptide whose best-supported evidence is topical and cosmetic, not systemic.

Hormonal signaling. A compound with genuine, ongoing academic research behind it.

• Kisspeptin peptide therapy — studied in human trials at Imperial College London for its role in reproductive hormone signaling, and still investigational.

The regulatory reality, stated plainly

This is the part most peptide marketing skips, so we will not skip it. As a class, "research peptides" are not the same thing as FDA-approved medications. Of the 13 compounds above, exactly one — tesamorelin — has genuine FDA approval, and that approval covers a single indication: reduction of excess visceral abdominal fat in HIV-associated lipodystrophy, sold under the brand name Egrifta. Every other compound discussed here is either investigational, approved for a different indication in a different country, discontinued in development, or has never completed a human efficacy trial at all.

Compounding law adds another layer. Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may only prepare certain categories of compounds, and the FDA has been explicit that some peptides now in wide circulation — retatrutide among them — are not permitted to be used in compounding under federal law because they have not been found safe and effective for any condition (FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss"). We think members deserve to know this before, not after, a conversation about any specific compound.

What peptides cannot do

No peptide protocol at Aeon is presented as a cure, a treatment, or a substitute for the fundamentals. The research literature behind these compounds, read honestly, studies them as potential adjuncts within a broader physiological picture — not as replacements for resistance training, sleep, or a protein-forward nutrition plan. A member who is not training, not sleeping, and not eating adequately is not a good candidate for a peptide conversation, and a responsible provider will say so. That is also why peptide therapy at Aeon connects directly to customized group training and personal training rather than existing as a stand-alone transaction.

Where the process starts

Every peptide conversation at Aeon begins the same way: a consultation with a licensed provider, followed by comprehensive lab work to establish a baseline. If hormonal symptoms are part of what brought you in, that conversation often runs alongside our hormone therapy program, since the two areas share lab markers and monitoring cadence. If weight management is the primary goal, our providers will also discuss it in the context of medical weight loss, where FDA-approved medication classes are a more established option than any peptide on this list. Nothing is decided until the labs are back and a licensed provider has reviewed them with you.